Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Clayton Luiz Borges
 -- 4240 2022-06-24 15:33:13 |
2 format change
Peter Tang
 -33 word(s) 4207 2022-06-29 05:24:20 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Inácio, M.M.;  Cruz-Leite, V.R.M.;  Moreira, A.L.E.;  Mattos, K.;  Paccez, J.D.;  Ruiz, O.H.;  Venturini, J.;  Melhem, M.D.S.C.;  Paniago, A.M.M.;  Soares, C.M.D.A.; et al. Neglected Human Systemic Mycoses Diagnosis. Encyclopedia. Available online: https://encyclopedia.pub/entry/24453 (accessed on 27 December 2024).
Inácio MM,  Cruz-Leite VRM,  Moreira ALE,  Mattos K,  Paccez JD,  Ruiz OH, et al. Neglected Human Systemic Mycoses Diagnosis. Encyclopedia. Available at: https://encyclopedia.pub/entry/24453. Accessed December 27, 2024.
Inácio, Moisés Morais, Vanessa Rafaela Milhomem Cruz-Leite, André Luís Elias Moreira, Karine Mattos, Juliano Domiraci Paccez, Orville Hernandez Ruiz, James Venturini, Marcia De Souza Carvalho Melhem, Anamaria Mello Miranda Paniago, Célia Maria De Almeida Soares, et al. "Neglected Human Systemic Mycoses Diagnosis" Encyclopedia, https://encyclopedia.pub/entry/24453 (accessed December 27, 2024).
Inácio, M.M.,  Cruz-Leite, V.R.M.,  Moreira, A.L.E.,  Mattos, K.,  Paccez, J.D.,  Ruiz, O.H.,  Venturini, J.,  Melhem, M.D.S.C.,  Paniago, A.M.M.,  Soares, C.M.D.A.,  Weber, S.S., & Borges, C.L. (2022, June 24). Neglected Human Systemic Mycoses Diagnosis. In Encyclopedia. https://encyclopedia.pub/entry/24453
Inácio, Moisés Morais, et al. "Neglected Human Systemic Mycoses Diagnosis." Encyclopedia. Web. 24 June, 2022.
Neglected Human Systemic Mycoses Diagnosis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/pathogens11050569

Systemic mycoses have been viewed as neglected diseases and they are responsible for deaths and disabilities around the world. Rapid, low-cost, simple, highly-specific and sensitive diagnostic tests are critical components of patient care, disease control and active surveillance. 

systemic mycoses diagnosis new targets in silico approaches

1. Introduction

The diagnosis of systemic mycoses can often be a challenge; however, it is very important to ensure the most appropriate treatment and clinical follow-up to monitor treatment effectiveness and side effects [1]. In this sense, a fast and accurate diagnosis could reduce the empirical antifungal therapies, impact on evolutionary selection pressure and contribute to resistance emergence management [2]. The main challenges are the lack of sensitive and specific methods for early diagnosis, the lack of standardization of serological and molecular tests, the wide antigenic variability of the clinical isolates, and the fastidious and slow-growing nature of some fungal species [1]. In addition, in low-prevalence areas, the positive predictive values of some nonculture-based tests could be significantly lower than in endemic areas.
Overall, histopathologic, direct and culture examinations from clinical samples are often used as the standard diagnostic for systemic mycoses. Although attempts to culture the microorganisms should always be pursued, culture is less effective when the fungal burden is low or depending on the clinical form or type of fungal infection. For instance, Pneumocystis jirovecii do not grow in vitro [3], and Paracoccidioides species are usually isolated in only 10 to 20% of culture examinations and can take up to a month to grow. Detection of antibodies or antigens provides valuable information about current disease and is important for the management of fungal infections. However, it is often unavailable for most mycoses. In addition, molecular approaches could be useful in detecting fungal DNA in low fungal burden cases, mainly from biological samples, but these approaches are still not well standardized (Table 1). Despite the challenges above, efforts to properly identify the pathological agent are pivotal, since early treatment, which depends on the correct diagnosis, can prevent complications and help to reduce the morbidity and mortality of the systemic fungal infections.

2. Paracoccidioidomycosis

Paracoccidioides spp. are endemic fungi restricted to Latin America [3][4][5]. The genus is composed of six human pathogenic species, Paracoccidioides brasiliensis, P. lutzii, P. americana, P. restrepiensis, P. venezuelensis [6] and the non-culturable P. loboi [7]. Brazil has a high incidence of PCM in the South, Southeast and Midwest regions, where the prevalence is related to agricultural work [5][8][9]. Rural workers are the most affected individuals, where males have a greater PCM distribution compared to females, which can be explained by female hormones [10]. The infection is triggered by the inhalation of conidia or mycelia propagules [5][11]. Inside the host, the inhaled fungus produces the yeast form that can disseminate to several sites, causing the acute/subacute or chronic disease forms, depending on host-parasite interaction [10][12].
The gold standard for definitively diagnosing PCM is the visualization of yeast cells with typical multiple budding aspects (“ship-pilot´s wheel” or “Mickey Mouse head”) in fresh examination of sputum or other clinical samples (scraped from lesion, lymph node aspiration, lesion sample, etc.). However, a low percentage of positive samples result in positive cultures. The detection of serum antibodies is diagnostically valuable and is particularly important to clinical follow-up as it allows the evaluation of the host response during specific antifungal treatment. The DID test has high specificity (100%) and sensitivity (from 65 to 100%) depending on the fungus isolate, endemic area of isolation, the culture conditions, the technique used and antigen profile [11][12][13][14]. In a comparison between WB versus DID with a purified glycoprotein of 43,000 Daltons from P. brasiliensis (Gp43), DID showed sensitivity (80%) and specificity (>90) of the test in an endemic area (different regions of Brazil), without false positive results or cross reaction [14]. Although ELISA (88–95% of specificity) is less specific than DID, mainly due to cross-reaction with histoplasmosis [15], it is highly sensitive (up to 100%), fast and suitable for PCM high-throughput screening [16]. Overall, among available serological techniques in the detection of serum antibodies, DID is the best method in patients with suspected PCM. On the other hand, Gp43 and Gp70 were described as good markers for monitoring antigen clearance during antifungal treatment by ELISA assay [17][18]. The usage of the Gp43 marker has become less useful since this antigen is usually not identified in the infections caused by P. lutzii [16][19]. The most common specimen employed in serological diagnostics is patient sera; however, the use of cerebrospinal fluid and bronchoalveolar lavage (BAL) specimens increases the sensitivity for antigen detection in the central nervous system and in pulmonary infections, respectively [20].
Table 1. Neglected Human Systemic Mycoses Diagnosis.

Mycosis

Diagnostic Test

Human Specimen

Time until Results

Accuracy

Advantage

Disadvantage

Infrastructural Resources

References

Paracoccidioidomycosis (PCM)

Double Immunodiffusion test

Serum

This technique requires much time.

Specificity 100% and Sensitivity 65–100%

The choice method in patients with suspected PCM without false positive results or cross reaction.

Low accuracy for determination of the patient’s cellular immunity important during the therapy.

Laborious. However, it is not expensive.

[12][13][17]

ELISA

Serum

This technique is fast.

Specificity 88–95%. Sensitivity 100%

Fast and suitable for PCM high-throughput screening.

Cross-reaction with Histoplasmmosis

Requires specific equipment and automatization.

[15][16]

Nucleic Acid testing

Blood, and clinical specimen

Result is obtained in a few hours.

Specificity 100%

Genotypic studies and clinical diagnosis performed directly from samples.

Need to standardize techniques based on DNA amplification for its real implementation.

Requires a specific and high-cost equipment.

[21]

Histoplasmosis

Immunodiffusion

Serum

This technique requires much time.

Sensitivity 60–70%

Rapid turnaround time

Not be used in immunocompromised individuals, since this group may present increases in false-negative results due to the compromise of the humoral response.

Low costs and simple infrastructure

[22]

Complement Fixation

Serum

This technique requires much time.

Sensitivity 60–70%

Rapid turnaround time

Laborious technique and requires well trained personnel

[22]

Enzyme Immunoassay

Serum, Plasma, Urine/CSF/BAL/Other Body Fluid.

Fast. (approximately 1.5 hours)

Sensitivity ranges 95–100% in urine, over 90% in serum and BAL antigens and 78% in cerebral spinal fluid (CSF)

Particularly important in AIDS patients who have disseminated histoplasmosis and who have large fungal burden

Serologic cross-reactions to Histoplasma-like antigens with Blastomycosis, Coccidioidomycosis, PCM and Aspergillosis

Requirement of specialized laboratories, expensive equipment, and well-trained personnel

[22][23]

Nucleic Acid testing

Blood and other body fluid.

The results are obtained in a few hours.

Specificity 100% and a sensitivity 67% to 100%.

Genotypic studies and clinical diagnosis performed directly from samples

Need to standardize techniques based on DNA amplification for its real implementation.

Requires specific and high-cost equipment.

[24][25]

Aspergillosis

ELISA assays galactomannan (GM) detection *

Serum, lung transplant recipients, sputum or bronchoalveolar lavage.

This technique is fast.

Sensitivity 60 to 100% and specificity 85 to 98%

GM levels are proportional to fungal burden in tissue, and present prognostic value

Both false positive and false negative results have been reported and cross reactivity.

Performed without the need for specialized equipment and reagents

[26][27][28]

Nucleic Acid testing

Serum, Lung transplant recipients, sputum or bronchoalveolar lavage.

The results are obtained in a few hours.

Specificity 100%

More sensitive and quick diagnosis

The lack of sensitivity and the difficulty in distinguishing between infection and colonization.

Requires specific equipment and has a high cost.

[29][30][31].

Coccidioidomycosis

Direct examination

Sputum or bronchoalveolar lavage or other biopsy material

This technique is fast.

N/A

The gold standard diagnostic method

The mold form of Coccidioides produces highly infectious arthroconidia as soon as 72 hours after initial growth.

Requires well trained personnel

[30][32]

Culture

Sputum or bronchoalveolar lavage or other biopsy material

Requires a lot of time.

N/A

The gold standard diagnostic method

This form represents a significant risk of inhalational exposure to laboratory personnel.

The potential exposure risks associated with aerosolization

[30][32][33]

Enzyme immunoassays

Serum, urinary, and cerebrospinal fluid

This technique is fast.

Sensitivity 88%. Specificity 90%

Antibody detection EIA is a sensitive and specific test, including high-risk patients’ samples, in detection of IgG and IgM antibodies

Maybe insensitive to early infection.

Performed without the need for specialized equipment and reagents

[30][32][34]

Cryptococcosis

Direct examination

Biopsy material

This technique is fast.

Sensitivity 60–90%

More sensitive and quick diagnosis

Lower sensitivity in HIV-negative patients in association with a low fungal burden.

Low-resource method

[35][36]

Culture exam

cerebrospinal fluid

1 to 2 weeks for definitive results

Sensitivity 85–95%

More sensitive. A gold standard for diagnostic

Need longer incubation periods up to three weeks.

The cultures are easily performed in any microbiology laboratory.

[37]

Nucleic Acid testing

Plasma or cerebrospinal fluid

The results are obtained in a few hours.

Specificity 100%

Allows the determination of the Cryptococcus species

Need to standardize techniques based on DNA amplification for its real implementation.

Requires a specific and high-cost equipment.

[38]

lateral flow assay

Plasma or cerebrospinal fluid

This technique is fast.

Sensitivity 90–100%

Provides a rapid diagnosis of cryptococcosis by detecting capsular antigen of Cryptococcus spp. In serum, plasma or CSF.

Low specificity (false positive 11% to 14%)

Low-costs

[39][40]
* Unusual in routine or applied in specific situations.
It is known that PCM control depends on an effective cellular immune response [41]. In this context, in order to prevent disease recurrence, it has been suggested that the suspension of treatment which is, in fact, too prolonged should occur after the patient’s cellular immune response recovery. So far, there is no specific test to assess the cellular immune response of PCM patients during treatment. Even though DID only assesses humoral immunity [17], the serological cure has often been used as an immunological cure parameter. However, this correlation is not accurate, since the DID assay has little antibody-detection power, and its low accuracy prevents the method’s validation for determining the patient’s cellular immunity. Depending on the host’s immune response and/or serological tests, patients may present high antibody titers at the end of treatment without presenting disease symptoms, while others may have low titers even in the presence of clinical symptoms [42].
Another factor that limits the use of the DID assay as a patient follow-up is the fact that about 10 to 40% of patients with PCM may not show positivity in the immunodiffusion assay [6]. This is probably due to the different antigenic profiles of the Paracoccidioides species and may affect the diagnosis of PCM. In this sense, the researchers' group recently identified a set of B-cell epitopes exclusive to the Paracoccidioides complex and a set specific to each fungal species, which were developed from an immunoproteomic approach [43]. These epitopes demonstrated promising results on serological tests (data not shown), however, they still need to be widely validated.

3. Histoplasmosis

Histoplasma capsulatum is the causative agent of American histoplasmosis in both immunocompromised and immunocompetent individuals. The mycosis is the largely distributed in North America; however, it has broken through the barriers of the endemic areas of Ohio and the Mississippi River and is found in other regions around the world [44][45][46]. The presence of microconidia or small hyphae fragments of H. capsulatum in soil contaminated by bird or bat feces is the primary scenario of host-contact, where the infection occurs via inhalation of the airborne fragments [47][48]. The histoplasmosis can manifest as acute, subacute, and chronic pulmonary in immunocompetent individuals, while the disseminated cases are more common in immunocompromised individuals, particularly during HIV infection [49][50].
Early and rapid detection of histoplasmosis is essential in preventing morbidity and mortality, but remains challenging mainly in impaired immune system patients, such as individuals suffering from AIDS. In immunocompromised individuals, histoplasmosis becomes progressive and spreads rapidly from the lungs to other organs and is known as progressive disseminated histoplasmosis (PDH) [25]. The definitive diagnosis of histoplasmosis is accomplished by isolation of H. capsulatum in culture, as well as by visualization of the yeast form in samples [22]. However, these procedures lack sensitivity and are time consuming. Thus, antibody detection methods represent the major tools currently in use for non-culture diagnosis, predominantly because of their availability and rapid turnaround time. Nevertheless, this method should not be used in immunocompromised individuals, since this group may present an increase in false-negative results due to the compromised humoral response. Furthermore, serologic cross-reactions to Histoplasma-like antigens occur in patients presenting other systemic mycoses, such as Blastomycosis, Coccidioidomycosis, PCM and Aspergillosis [51][52][53].
Due to the high specificity of H. capsulatum, the identification of anti-H and anti-M antibodies using antigenic extract (histoplasmin) from mycelial culture is notably useful in serological diagnosis of histoplasmosis. The sensitivity of antibody detection by ID or CF is between 60% and 70% [22]. On the other hand, detection of the circulating H. capsulatum polysaccharide antigen in urine and serum is particularly important in AIDS patients who have disseminated histoplasmosis. Antigenuria can be used for monitoring the host response to antifungal treatment [22], while identification of antigens in BAL is useful in pulmonary histoplasmosis [54]. Recent advances highlight MiraVista Diagnostics, a company that developed three generations of EIA assay, with sensitivity ranges of between 95–100% in urine, over 90% in serum and BAL antigens, and 78% in cerebral spinal fluid (CSF) [22]. However, the high cost of testing is still an obstacle in using the assay for the diagnosis of histoplasmosis.

4. Coccidioidomycosis

Another endemic mycosis that primarily affects the lungs is coccidioidomycosis, caused by Coccidioides spp. This genus comprises Coccidioides immitis and Coccidioides posadasii, which also cause pulmonary disease in immunocompetent individuals. The endemic region of Coccidioides spp. is that with an arid climate where the infection occurs predominantly in the dry seasons [55]. Coccidioides spp. are prevalent in Mexico and the southwestern United States (Arizona, Texas and California) where the endemic areas were determined by skin test using spherulin or coccidioidin antigen preparations [56][57]. In South America, Coccidioides is present in Bolivia, Paraguay, Argentina, and Brazil [58][59][60]. The infection occurs after fungi arthroconidia inhalation, which reach the host’s pulmonary system and undergo dimorphic transition to yeast or spherule infective forms [57][61]. The clinical manifestation of coccidioidomycosis ranges from pulmonary infection to life-threatening pneumonia, to the dissemination of the infection to the tissues of the human body [62].
Clinical information is important, but the identification of Coccidioides on pathologic examinations or the isolation of fungus in culture are the gold standards for diagnosis of coccidioidomycosis. However, the use of these techniques is less frequent compared to the large number of actual cases, lack sensitivity, are time consuming, and require a degree of expertise to recognize the fungus [31][33][63].
Serology is the most used method of diagnosis [64]. Among methods used, EIA for antibody detection is the most regularly employed. Furthermore, two methods are commercially available, the Meridian Premier Coccidioides EIA (Cincinnati, OH, USA) and the Immuno-Mycologics Inc. (IMMY) Omega Coccidioides EIA (Norman, OK, USA), which are performed in most major reference laboratories and some laboratory hospitals. An alternative test is performed by detecting immunoglobulin G (IgG) by CF or ID and immunoglobulin M (IgM) antibodies by immunodiffusion. However, EIA is simpler to perform and provides same-day results, while ID and CF are difficult to execute and require 2 to 6 days to provide results [65].
A new test was developed by MiraVista Diagnostic (MVista), which demonstrates a sensitivity for IgG and/or IgM of 88% compared to 60% for ID and 66% for CF. Furthermore, the EIA MVista maintained similarly high sensitivity in immunocompromised patients (IgG 83% and IgM 56%) for whom ID sensitivity was reduced (IgG 40% and IgM 30%). It also maintained a 90% specificity and demonstrated low-to-moderate rates of cross-reactivity with other endemic mycoses (32% histoplasmosis and 8% blastomycosis) [34].
Malo et al. (2020) evaluated three commercial enzyme immunoassay kits: the IMMY omega EIA and the Meridian Premier EIA (for IgG detection) and IgM with the new EIA test, MVista Coccidioides test, and observed that the sensitivity of the IgG antibody detection was 87.4% using the MVista test compared to 46.6% for the IMMY test and 70.9% for the Meridian test. Similarly, the specificity of IgG and IgM antibodies was higher for the MVista EIA (90% and 95.3%, respectively), indicating that the MVista Coccidioides antibody detection EIA is a sensitive and specific test, including high-risk patients’ samples, in the detection of IgG and IgM antibodies [65].
Nevertheless, serologic tests for coccidioidomycosis may be insensitive to early infection [66]. Therefore, to minimize the potential for false-negative testing, serial serological testing is recommended, necessitating an initial serology followed by a second specimen from the convalescent phase of the disease. On the other hand, an isolated positive IgM EIA test should be followed closely with clinical correlation and subsequent diagnostic testing [66]. In many instances, this will generate serial testing, repeat EIA testing for IgM and IgG, or confirmatory testing by the immunodiffusion-tube precipitin reaction [67].
Recently, a monoclonal antibody ELISA test against coccidioidal CTS1 antigen has been developed [68]. CTS1 is also known as the “CF” antigen also used in coccidioidomycosis serodiagnosis by CF and ID tests.

5. Aspergillosis

Aspergillus species are agents of pulmonary aspergillosis. Despite numbering in their hundreds, only a few species have an impact on human health. The most clinically important fungi are: Aspergillus fumigatus [69][70], A. flavus [71] A. nidulans [72], A. niger [73] and A. terreus [74]. Aspergillus-related pathologies are caused by inhalation of airborne conidia which are encountered in air, soil, water, outdoor plants, as well as in hospitals [75]. Aspergillus species continue to be an important cause of life-threatening infection in immunocompromised patients, particularly those under prolonged corticosteroid therapy, immunosuppressive drugs, or with hematological malignancies, or people infected with HIV or individuals suffering from AIDS [76]. Aspergillosis presents with a wide range of clinical syndromes, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and the most severe, invasive pulmonary aspergillosis (IPA), which is linked to high mortality rates [70][75][77] Chronic pulmonary aspergillosis has been recognized as an important and neglected fungal infection [78][79][80][81]. It is estimated that approximately three million cases of CPA aspergillosis occurred annually, being 2000 to 160,000 people after tuberculosis treatment, annually, with 50% case fatality in 5 years [82].
Diagnosis of aspergilloma or invasive aspergillosis (IA) can be difficult, and currently alternatives include laboratory tests such as histopathologic/cytologic and culture examination. Serum detection of galactomannan (GM) and (1,3)-beta-D glucan (BDG) were also recommended to be used in patients with specific clinical conditions, such as hematologic malignancy as well as submitted to allogeneic hematopoietic stem cell transplant [83][84]. GM is a cell wall component of Aspergillus that is released by the fungus [26] and can be detected through latex agglutination or ELISA assays. It has been suggested that GM levels are proportional to the fungal burden in tissues and present prognostic value [27]. In this context, IMMY diagnostics has developed an antigen assay lateral flow device with a sensitivity of 40% and specificity of 80%. In addition, the GM assay uses sandwich EIA for the diagnosis of invasive aspergillosis, although it can also be found on the H. capsulatum and Fusarium spp. cell walls [85][86].
CPA is possibly the systemic mycosis where serological testing is most useful. While antigen detection tests such as galactomannan are important in IA, it is only positive in about 25% of CPA patients [87]. Anti-aspergillus tests are, however, positive in over 90% of patients. In practice, precipitation techniques were replaced by an ELISA IgG antibody detection test [88], because it was the fastest, the most sensitive [89], and easily automated, although it is lacking in specificity. In the last decade, several commercial Aspergillus-specific IgG ELISAs have been developed and are now widely used in CPA diagnosis [88].
Finally, the ABPA is a hypersensitivity reaction test to Aspergillus species (generally A. fumigatus) that occurs almost exclusively in patients with cystic fibrosis or, less commonly, with asthma. The ABPA diagnosis can be confirmed by IgE levels and A. fumigatus–specific antibody detection and by visualization of the yeast forms in clinical samples with the help of fungus-enhancing staining, such as calcofluor white, or using histopathology techniques [84].

6. Cryptococcosis

Cryptococcal meningitis, the most severe form of this systemic mycosis, it is listed in the G-Finder report, and meets the WHO and PLOS definitions of a neglected disease, affecting disproportionately populations in poverty, causing high morbidity and mortality, and being neglected by research [81][90][91].
Two complexes of the Cryptococcus species, which determine epidemiologically distinct clinical conditions, are responsible for cryptococcosis. Cryptococcus neoformans and C. gattii are associated with conditions of host cellular immunodepression. In the past, C. gattii, was considered the agent of primary cryptococcosis in apparently normal hosts, however, both have been found in immunocompromised and immunocompetent individuals [92][93]. Furthermore, both complexes cause meningoencephalitis, which has a severe and fatal evolution and can be accompanied by evident lung injury. Additional effects of the infection include fungemia and secondary foci for skin, bones, kidneys, and adrenal, among others [93][94].
Currently, the diagnosis of cryptococcosis, as well as most systemic mycoses, is performed in routine laboratories by mycological examination using histopathological and immunological tests. For better observation of the capsule, a drop of Indian ink dye should be added on a microscope slide. The sensitivity of this test assessed on CSF samples ranges from 60% to 90%, according to the analyst’s expertise and according to the fungal load. However, direct examination of blood samples has low sensitivity, and its use has not been recommended [35][36][95].
Isolation of the etiologic agent by culture allows morphological, biochemical and molecular analysis of the clinical strain. For CSF samples, the culture exam sensitivity is from 85% to 95%, according to the disease stage and fungal load [37]. The presumptive identification of the Cryptococcus genus is performed by microscopic examination of a portion of the culture that allows the presence of yeast to be checked with a capsule without the production of hyphae (some strains may form short pseudo hyphae). The positive urease test minimally complements the presumptive genus identification. The characteristic production of melanin in Guizzotia absynica agar is essential in the diagnostic laboratory, to show that it is a question of which pathogenic species is being examined [38]. For histopathological examination, the sample should be stained with Mayer’s mucicarmine, that highlights the capsule in red and is therefore particularly useful in hypocapsulated strain infections [96]. Meanwhile, the Fontana–Masson staining shows the melanin of the cell wall and, therefore, it is also specific for both Cryptococcus complexes species, because in the other Cryptococcus members the reaction is negative. Other methods, such as periodic acid from Schiff (PAS) and Groccot–Gomori can be used, however, they are non-specific. Hematoxylin–eosin staining is also useful to check the tissue reaction profile, which is quite poor in general, but eventually allows the verification of granulomatous reaction in immunocompetent patients or infections with hypocapsulated strains [97]. In addition, the MALDI-TOF MS approach allows the correct identification of species from the two complexes, provided commercial standard databases are properly enriched [98][99].
Immunological examination provides a rapid diagnosis of cryptococcosis by detecting the capsular antigen of Cryptococcus spp. in serum, plasma or CSF. Quantitative examination by antigen titration has a prognostic value. In cryptococcal infection, unlike other invasive mycoses, the humoral response, assessed by antibody quantification, is poor and therefore this method is not suitable for diagnosis. Otherwise, the capsular antigen (Cryptococcus Antigen-CrAg), represented by polysaccharide molecules, is soluble in several body fluids and can be detected in CSF in cases of meningitis and in the serum of patients with and without meningitis weeks to months before symptoms of the disease present [100]. All species of Cryptococcus spp. have capsular antigens and, therefore, a positive test indicates active disease, but does not allow identification of the species of the etiologic agent.
The search for capsular antigens was traditionally carried out by an agglutination test with latex particles sensitized with antibodies against Cryptococcus. A more recent qualitative and quantitative test for capsular antigens carried out on strip has been available. It was developed to be cheaper and simpler, with the point of care based on the immunochromatography reaction denominated lateral flow assay (LFA). The test stripes can be stored, for up to two years, outside refrigeration and have been designated as point-of-care tests. Other manufacturers, from France, China, and Denmark, commercialize LFA for cryptococcosis diagnosis, but few studies have been conducted for evaluating the performance of the new trend marks, in comparison to the IMMY LFA. The majority of the following information was obtained using the north American test [101]. The LFA test is more sensitive in the detection of polysaccharides from the four Cryptococcus serotypes compared to the latex test. For children, data on the accuracy of the test are limited, although it is estimated that its performance is similar to that observed in adults [102].
The LFA test has greater analytical sensitivity compared to others when it comes to antigens of both C. neoformans and C. gattii [103]. A small amount of sample is sufficient to diagnose cryptococcal meningitis, initial or advanced, with sensitivity from 97.6% to 100% (serum) and between 94.0% to 100% (CSF) [40][89][104][105] without the need for laboratory equipment or technical expertise, which makes the test ideal for regions with limited resources [106]. The specificity of the test in serum reaches 98.1% and in CSF 98.9%. For pulmonary forms there are few studies with LFA, indicating that the test is better than latex, since the sensitivity reaches 100% with serum samples [102].
For HIV-positive patients with cryptococcal meningitis, samples of whole blood, collected on a fingertip, eluted on the LFA test strip, resulted in equal sensitivity (95%) to that obtained with serum and CSF samples. The specificity of the test, performed with sera from HIV positive patients with other diseases of the central nervous system, was 100%, but urine samples from these patients were positive in only 80% of the cases in the same study, indicating limitation in the use of this sample for antigen research [107]. In fact, the specificity of the test with urine samples is still too unreliable to recommend this procedure [108][109].
LFA is particularly useful in patients with HIV infection in whom early detection of cryptococcosis, followed by pre-emptive antifungal therapy with fluconazole (screen and treat strategy), reduces disease progress and mortality from meningitis [109][110][111][112]. The WHO recommends antigen research (serum, CSF, plasma, whole blood) for screening cryptococcosis in adult and adolescent populations in regions where the prevalence of cryptococcal antigenemia is high (>3%), although it appears to be cost-effective in regions with lower antigenic prevalence, such as 0.06% [39][113].

References

  1. Salzer, H.J.F.; Burchard, G.; Cornely, O.A.; Lange, C.; Rolling, T.; Schmiedel, S.; Libman, M.; Capone, D.; Le, T.; Dalcolmo, M.P.; et al. Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. Respiration 2018, 96, 283–301.
  2. Yeo, S.F.; Wong, B. Current Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections. Clin. Microbiol. Rev. 2002, 15, 465–484.
  3. Liu, Y.; Fahle, G.A.; Kovacs, J.A. Inability to Culture Pneumocystis jirovecii. mBio 2018, 9, e00939-18.
  4. Martinez, R. New Trends in Paracoccidioidomycosis Epidemiology. J. Fungi 2017, 3, 1.
  5. Bocca, A.L.; Amaral, A.C.; Teixeira, M.M.; Sato, P.K.; Sato, P.; Shikanai-Yasuda, M.A.; Soares Felipe, M.S. Paracoccidioidomycosis: Eco-Epidemiology, Taxonomy and Clinical and Therapeutic Issues. Future Microbiol. 2013, 8, 1177–1191.
  6. Shikanai-Yasuda, M.A.; Mendes, R.P.; Colombo, A.L.; Queiroz-Telles, F.D.; Kono, A.S.G.; Paniago, A.M.M.; Nathan, A.; do Valle, A.C.F.; Bagagli, E.; Benard, G.; et al. Brazilian Guidelines for the Clinical Management of Paracoccidioidomycosis. Rev. Soc. Bras. Med. Trop. 2017, 50, 715–740.
  7. Shankar, J.; Restrepo, A.; Clemons, K.V.; Stevens, D. A Hormones and the Resistance of Women to Paracoccidioidomycosis. Clin. Microbiol. Rev. 2011, 24, 296–313.
  8. Terçarioli, G.R.; Bagagli, E.; Reis, G.M.; Theodoro, R.C.; Bosco, S.D.M.G.; Macoris, S.A.D.G.; Richini-Pereira, V.B. Ecological Study of Paracoccidioides brasiliensis in Soil: Growth Ability, Conidia Production and Molecular Detection. BMC Microbiol. 2007, 7, 92.
  9. Brummer, E.; Castaneda, E.; Restrepo, A. Paracoccidioidomycosis: An Update. Clin. Microbiol. Rev. 1993, 6, 89–117.
  10. Mendes, R.P.; Cavalcante, R.D.S.; Marques, S.A.; Marques, M.E.A.; Venturini, J.; Sylvestre, T.F.; Paniago, A.; Pereira, A.C.; Silva, J.; Fabro, A.T.; et al. Paracoccidioidomycosis: Current Perspectives from Brazil. Open Microbiol. J. 2017, 11, 224–282.
  11. Paracoccidioidomycosis, 46th ed.; Franco, M.; da Silva Lacaz, C.; Restrepo-Moreno, A.; Del Negro, G. (Eds.) CRC Press: Boca Raton, FL, USA, 2018; ISBN 9781351075329.
  12. Cano, L.E.; Restrepo, A. Predictive Value of Serologic Tests in the Diagnosis and Follow-up of Patients with Paracoccidioidomycosis. Rev. Inst. De Med. Trop. São Paulo 1987, 29, 276–283.
  13. Moreto, T.C.; Marques, M.E.A.; de Oliveira, M.L.S.C.; Moris, D.V.; de Carvalho, L.R.; Mendes, R.P. Accuracy of Routine Diagnostic Tests Used in Paracoccidioidomycosis Patients at a University Hospital. Trans. R. Soc. Trop. Med. Hyg. 2011, 105, 473–478.
  14. Perenha-Viana, M.C.Z.; Gonzales, I.A.A.; Brockelt, S.R.; Machado, L.N.C.; Svidzinski, T.I.E. Serological Diagnosis of Paracoccidioidomycosis through a Western Blot Technique. Clin. Vaccine Immunol. 2012, 19, 616–619.
  15. Puccia, R.; Travassos, L.R. The 43-KDa Glycoprotein from the Human Pathogen Paracoccidioides brasiliensis and Its Deglycosylated Form: Excretion and Susceptibility to Proteolysis. Arch. Biochem. Biophys. 1991, 289, 298–302.
  16. de Fatimada Silva, J.; de Oliveira, H.C.; Marcos, C.M.; Assato, P.A.; Fusco-Almeida, A.M.; Mendes-Giannini, M.J.S. Advances and Challenges in Paracoccidioidomycosis Serology Caused by Paracoccidioides Species Complex: An Update. Diagn. Microbiol. Infect. Dis. 2016, 84, 87–94.
  17. Soares Mendes Giannini, M.J.; Bueno, J.P.; Aparecida Shikanai-Yasuda, M.; Stolf, A.M.S.; Masuda, A.; Amato Neto, V.; Ferreira, A.W. Antibody Response to the 43 KDa Glycoprotein of Paracoccidioides brasiliensis as a Marker for the Evaluation of Patients under Treatment. Am. J. Trop. Med. Hyg. 1990, 43, 200–206.
  18. Marques da Silva, S.H.; Queiroz-Telles, F.; Colombo, A.L.; Blotta, M.H.S.L.; Lopes, J.D.; Pires de Camargo, Z. Monitoring Gp43 Antigenemia in Paracoccidioidomycosis Patients during Therapy. J. Clin. Microbiol. 2004, 42, 2419–2424.
  19. Gegembauer, G.; Araujo, L.M.; Pereira, E.F.; Rodrigues, A.M.; Paniago, A.M.M.; Hahn, R.C.; Camargo, Z.P. de Serology of Paracoccidioidomycosis Due to Paracoccidioides lutzii. PLoS Negl. Trop. Dis. 2014, 8, e2986.
  20. De Camargo, Z.P. Serology of Paracoccidioidomycosis. Mycopathologia 2008, 165, 289–302.
  21. Pinheiro, B.G.; Hahn, R.C.; de Camargo, Z.P.; Rodrigues, A.M. Molecular Tools for Detection and Identification of Paracoccidioides Species: Current Status and Future Perspectives. J. Fungi 2020, 6, 293.
  22. Myint, T.; Leedy, N.; Cari, E.V.; Wheat, L.J. Hiv-Associated Histoplasmosis: Current Perspectives. HIV/AIDS-Res. Palliat. Care 2020, 12, 113–125.
  23. Abdallah, W.; Myint, T.; Larue, R.; Minderman, M.; Gunn, S.; Wheat, L.J.; Hage, C.A. Diagnosis of Histoplasmosis Using the MVista Histoplasma Galactomannan Antigen Qualitative Lateral Flow-Based Immunoassay: A Multicenter Study. Open Forum Infect. Dis. 2021, 8, ofab454.
  24. Vasconcellos, I.C.D.S.; Lana, D.F.D.; Pasqualotto, A.C. The Role of Molecular Tests in the Diagnosis of Disseminated Histoplasmosis. J. Fungi 2020, 6, 1.
  25. Azar, M.M.; Hage, C.A. Laboratory Diagnostics for Histoplasmosis. J. Clin. Microbiol. 2017, 55, 1612–1620.
  26. Latge, J.P.; Kobayashi, H.; Debeaupuis, J.P.; Diaquin, M.; Sarfati, J.; Wieruszeski, J.M.; Parra, E.; Bouchara, J.P.; Fournet, B. Chemical and Immunological Characterization of the Extracellular Galactomannan of Aspergillus fumigatus. Infect. Immun. 1994, 62, 5424–5433.
  27. Verdaguer, V.; Walsh, T.J.; Hope, W.; Cortez, K.J. Galactomannan Antigen Detection in the Diagnosis of Invasive Aspergillosis. Expert Rev. Mol. Diagn. 2007, 7, 21–32.
  28. Herrera, S.; Husain, S. Current State of the Diagnosis of Invasive Pulmonary Aspergillosis in Lung Transplantation. Front. Microbiol. 2019, 10, 3273.
  29. Egger, M.; Jenks, J.D.; Hoenigl, M.; Prattes, J. Blood Aspergillus PCR: The Good, the Bad, and the Ugly. J. Fungi 2020, 6, 18.
  30. Hage, C.A.; Carmona, E.M.; Epelbaum, O.; Evans, S.E.; Gabe, L.M.; Haydour, Q.; Knox, K.S.; Kolls, J.K.; Hassan, M. Erratum: Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2019, 200, 1326.
  31. Barton, R.C. Laboratory Diagnosis of Invasive Aspergillosis: From Diagnosis to Prediction of Outcome. Scientifica 2013, 2013, 459405.
  32. Adams, M.; Lainhart, W. A Review of Diagnostics for Coccidiomycosis. Clin. Microbiol. Newsl. 2021, 43, 135–141.
  33. Twarog, M.; Thompson, G.R. Coccidioidomycosis: Recent Updates. Semin. Respir. Crit. Care Med. 2015, 36, 746–755.
  34. Malo, J.; Holbrook, E.; Zangeneh, T.; Strawter, C.; Oren, E.; Robey, I.; Erickson, H.; Chahal, R.; Durkin, M.; Thompson, C.; et al. Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the Miravista IgG and IgM Detection Enzyme Immunoassay. J. Clin. Microbiol. 2017, 55, 893–901.
  35. Boulware, D.; Rolfes, M.A.; Rajasingham, R.; Von Hohenberg, M.; Qin, Z.; Taseera, K.; Schutz, C.; Kwizera, R.; Butler, E.K.; Meintjes, G.; et al. Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast. Emerg. Infect. Dis. 2014, 20, 45.
  36. Chammard, T.B.; Temfack, E.; Lortholary, O.; Alanio, A. Diagnostic and Therapeutic Strategies in Cryptococcosis: Impact on Outcome. Mem. Inst. Oswaldo Cruz 2018, 113, e180050.
  37. Masur, H.; Brooks, J.T.; Benson, C.A.; Holmes, K.K.; Pau, A.K.; Kaplan, J.E. Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 2014, 58, 1308–1311.
  38. Setianingrum, F.; Rautemaa-Richardson, R.; Denning, D.W. Pulmonary Cryptococcosis: A Review of Pathobiology and Clinical Aspects. Med. Mycol. 2019, 57, 133–150.
  39. Rajasingham, R.; Rolfes, M.A.; Birkenkamp, K.E.; Meya, D.B.; Boulware, D.R. Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Med. 2012, 9, e1001316.
  40. Hansen, J.; Slechta, E.S.; Gates-Hollingsworth, M.A.; Neary, B.; Barker, A.P.; Bauman, S.; Kozel, T.R.; Hanson, K.E. Large-Scale Evaluation of the Immuno-Mycologics Lateral Flow and Enzyme-Linked Immunoassays for Detection of Cryptococcal Antigen in Serum and Cerebrospinal Fluid. Clin. Vaccine Immunol. 2013, 20, 52–55.
  41. Del Negro, G.M.B.; Hong, M.A.; Duarte, A.J.S.; Shikanai-Yasuda, M.A.; Batista, L.; Benard, G. Antigen-Specific Immunosuppression in Paracoccidioidomycosis. Am. J. Trop. Med. Hyg. 1996, 54, 7–12.
  42. Kamikawa, C.M.; Mendes, R.P.; Vicentini, A.P. Standardization and Validation of Dot-ELISA Assay for Paracoccidioides brasiliensis Antibody Detection. J. Venom. Anim. Toxins Incl. Trop. Dis. 2017, 23, 11.
  43. Moreira, A.L.E.; Oliveira, M.A.P.; Silva, L.O.S.; Inácio, M.M.; Bailão, A.M.; Parente-Rocha, J.A.; Cruz-Leite, V.R.M.; Paccez, J.D.; de Almeida Soares, C.M.; Weber, S.S.; et al. Immunoproteomic Approach of Extracellular Antigens from Paracoccidioides Species Reveals Exclusive B-Cell Epitopes. Front. Microbiol. 2020, 10, 2968.
  44. Teixeira, M.D.M.; Patané, J.S.L.; Taylor, M.L.; Gómez, B.L.; Theodoro, R.C.; de Hoog, S.; Engelthaler, D.M.; Zancopé-Oliveira, R.M.; Felipe, M.S.S.; Barker, B.M. Worldwide Phylogenetic Distributions and Population Dynamics of the Genus Histoplasma. PLoS Negl. Trop. Dis. 2016, 10, e0004732.
  45. Oladele, R.O.; Ayanlowo, O.O.; Richardson, M.D.; Denning, D.W. Histoplasmosis in Africa: An Emerging or a Neglected Disease? PLoS Negl. Trop. Dis. 2018, 12, e0006046.
  46. Bahr, N.C.; Antinori, S.; Wheat, J.; Sarosi, G.A. Histoplasmosis Infections Worldwide: Thinking Outside of the Ohio River Valley. Curr. Trop. Med. Rep. 2016, 176, 139–148.
  47. Garfoot, A.L.; Reppleye, C.A. Histoplasma capsulatum Surmounts Obstacles to Intracellular Pathogenesis. FEBS J. 2016, 283, 619–633.
  48. Ray, S.C.; Rappleye, C.A. Flying under the Radar: Histoplasma capsulatum Avoidance of Innate Immune Recognition. Semin. Cell Dev. Biol. 2018, 89, 91–98.
  49. Kauffman, C.A. Histoplasmosis: A Clinical and Laboratory Update. Clin. Microbiol. Rev. 2007, 20, 115–132.
  50. Wheat, L.J.; Azar, M.M.; Bahr, N.C.; Spec, A.; Relich, R.F.; Hage, C. Histoplasmosis. Infect. Dis. Clin. N. Am. 2016, 30, 207–227.
  51. Connolly, P.A.; Durkin, M.M.; Lemonte, A.M.; Hackett, E.J.; Wheat, L.J. Detection of Histoplasma Antigen by a Quantitative Enzyme Immunoassay. Clin. Vaccine Immunol. 2007, 14, 1587–1591.
  52. Guimarães, A.J.; Nosanchuk, J.D.; Zancopé-Oliveira, R.M. Diagnosis of Histoplasmosis. Braz. J. Microbiol. 2006, 37, 1–13.
  53. Scheel, C.M.; Gómez, B.L. Diagnostic Methods for Histoplasmosis: Focus on Endemic Countries with Variable Infrastructure Levels. Curr. Trop. Med. Rep. 2014, 1, 129–137.
  54. Hage, C.A.; Davis, T.E.; Fuller, D.; Egan, L.; Witt, J.R.; Wheat, L.J.; Knox, K.S. Diagnosis of Histoplasmosis by Antigen Detection in BAL Fluid. Chest 2010, 137, 623–628.
  55. Colombo, A.L.; Tobn, A.; Restrepo, A.; Queiroz-Telles, F.; Nucci, M. Epidemiology of Endemic Systemic Fungal Infections in Latin America. Med. Mycol. 2011, 49, 785–798.
  56. Brown, J.; Benedict, K.; Park, B.J.; Thompson, G.R. Coccidioidomycosis: Epidemiology. Clin. Epidemiol. 2013, 5, 185–197.
  57. Sunenshine, R.H.; Anderson, S.; Erhart, L.; Vossbrink, A.; Kelly, P.C.; Engelthaler, D.; Komatsu, K. Public Health Surveillance for Coccidioidomycosis in Arizona. Ann. N. Y. Acad. Sci. 2007, 1111, 96–102.
  58. Laniado-Laborín, R.; Arathoon, E.G.; Canteros, C.; Muñiz-Salazar, R.; Rendon, A. Coccidioidomycosis in Latin America. Med. Mycol. 2019, 57, S46–S55.
  59. Giacomazzi, J.; Baethgen, L.; Carneiro, L.C.; Millington, M.A.; Denning, D.W.; Colombo, A.L.; Pasqualotto, A.C. The Burden of Serious Human Fungal Infections in Brazil. Mycoses 2016, 59, 145–150.
  60. de Aguiar Cordeiro, R.; Brilhante, R.S.N.; Rocha, M.F.G.; Bandeira, S.P.; Fechine, M.A.B.; de Camargo, Z.P.; Sidrim, J.J.C. Twelve Years of Coccidioidomycosis in Ceará State, Northeast Brazil: Epidemiologic and Diagnostic Aspects. Diagn. Microbiol. Infect. Dis. 2010, 66, 65–72.
  61. Kirkland, T.N.; Fierer, J. Coccidioides immitis and posadasii; a Review of Their Biology, Genomics, Pathogenesis, and Host Immunity. Virulence 2018, 9, 1426–1435.
  62. Nguyen, C.; Barker, B.M.; Hoover, S.; Nix, D.E.; Ampel, N.M.; Frelinger, J.A.; Orbach, M.J.; Galgiani, J.N. Recent Advances in Our Understanding of the Environmental, Epidemiological, Immunological, and Clinical Dimensions of Coccidioidomycosis. Clin. Microbiol. Rev. 2013, 26, 505–525.
  63. Gabe, L.M.; Malo, J.; Knox, K.S. Diagnosis and Management of Coccidioidomycosis. Clin. Chest Med. 2017, 38, 417–433.
  64. Malo, J.; Luraschi-Monjagatta, C.; Wolk, D.M.; Thompson, R.; Hage, C.A.; Knox, K.S. Update on the Diagnosis of Pulmonary Coccidioidomycosis. Ann. Am. Thorac. Soc. 2014, 11, 243–253.
  65. Malo, J.; Holbrook, E.; Zangeneh, T.; Strawter, C.; Oren, E.; Robey, I.; Erickson, H.; Carranza-Chahal, R.; Durkin, M.; Thompson, C.; et al. Comparison of Three Anti-Coccidioides Antibody Enzyme Immunoassay Kits for the Diagnosis of Coccidioidomycosis. Med. Mycol. 2020, 58, 774–778.
  66. Blair, J.E.; Coakley, B.; Santelli, A.C.; Hentz, J.G.; Wengenack, N.L. Serologic Testing for Symptomatic Coccidioidomycosis in Immunocompetent and Immunosuppressed Hosts. Mycopathologia 2006, 162, 317–324.
  67. Pappagianis, D. Serologic Studies in Coccidioidomycosis. Semin. Respir. Infect. 2001, 16, 242–250.
  68. Grill, F.J.; Grys, T.E.; Grill, M.F.; Roeder, A.; Blair, J.E.; Lake, D.F. Development of a Quantitative Antigen Assay to Detect Coccidioidal Chitinase-1 (CTS1) in Human Serum. Open Forum Infect. Dis. 2021, 8, ofab344.
  69. Latgé, J.-P.; Chamilos, G. Aspergillus fumigatus and Aspergillosis in 2019. Clin. Microbiol. Rev. 2020, 33, e00140-18.
  70. Mccormick, A.; Loeffler, J.; Ebel, F. Aspergillus fumigatus: Contours of an Opportunistic Human Pathogen. Cell. Microbiol. 2010, 12, 1535–1543.
  71. Krishnan, S.; Manavathu, E.K.; Chandrasekar, P.H. Aspergillus flavus: An Emerging Non-fumigatus Aspergillus Species of Significance. Mycoses 2009, 52, 206–222.
  72. Henriet, S.S.V.; Verweij, P.E.; Warris, A. Aspergillus nidulans and Chronic Granulomatous Disease: A Unique Host-Pathogen Interaction. J. Infect. Dis. 2012, 206, 1128–1137.
  73. Person, A.K.; Chudgar, S.M.; Norton, B.L.; Tong, B.C.; Stout, J.E. Aspergillus niger: An Unusual Cause of Invasive Pulmonary Aspergillosis. J. Med. Microbiol. 2010, 59, 834–838.
  74. Pastor, F.J.; Guarro, J. Treatment of Aspergillus terreus Infections: A Clinical Problem Not yet Resolved. Int. J. Antimicrob. Agents 2014, 44, 281–289.
  75. Kousha, M.; Tadi, R.; Soubani, A.O. Pulmonary Aspergillosis: A Clinical Review. Eur. Respir. Rev. 2011, 20, 156–174.
  76. Kontoyiannis, D.; Bodey, G. Invasive Aspergillosis in 2002: An Update. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21, 161–172.
  77. Kanj, A.; Abdallah, N.; Soubani, A.O. The Spectrum of Pulmonary Aspergillosis. Respir. Med. 2018, 141, 121–131.
  78. Godet, C.; Alastruey-Izquierdo, A.; Flick, H.; Hennequin, C.; Mikilps-Mikgelbs, R.; Munteanu, O.; Page, I.; Seidel, D.; Salzer, H.J.F. A CPAnet Consensus Statement on Research Priorities for Chronic Pulmonary Aspergillosis: A Neglected Fungal Infection That Requires Attention. J. Antimicrob. Chemother. 2018, 73, 280–286.
  79. Niu, Y.; Li, J.; Shui, W.; Li, D.; Yu, C.; Fu, X.; Zhang, C. Clinical Features and Outcome of Patients with Chronic Pulmonary Aspergillosis in China: A Retrospective, Observational Study. J. De Mycol. Médicale 2020, 30, 101041.
  80. Shah, A.; Armstrong-James, D.; Chotirmall, S.H. Respiratory Mycoses: A Call to Action to Recognize, Educate and Invest. Mycopathologia 2021, 186, 569–573.
  81. Rodrigues, M.L.; Nosanchuk, J.D. Fungal Diseases as Neglected Pathogens: A Wake-up Call to Public Health Officials. PLOS Negl. Trop. Dis. 2020, 14, e0007964.
  82. Bongomin, F.; Gago, S.; Oladele, R.; Denning, D. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. J. Fungi 2017, 3, 57.
  83. Donnelly, J.P.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis. 2020, 71, 1367–1376.
  84. Patterson, T.F.; Thompson, G.R.; Denning, D.W.; Fishman, J.A.; Hadley, S.; Herbrecht, R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Nguyen, M.H.; et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016, 63, e1–e60.
  85. Tortorano, A.M.; Esposto, M.C.; Prigitano, A.; Grancini, A.; Ossi, C.; Cavanna, C.; Cascio, G. lo Cross-Reactivity of Fusarium spp. in the Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay. J. Clin. Microbiol. 2012, 50, 1051–1053.
  86. Wheat, L.J.; Hackett, E.; Durkin, M.; Connolly, P.; Petraitiene, R.; Walsh, T.J.; Knox, K.; Hage, C. Histoplasmosis-Associated Cross-Reactivity in the BioRad Platelia Aspergillus Enzyme Immunoassay. Clin. Vaccine Immunol. 2007, 14, 638–640.
  87. Fraczek, M.G.; Kirwan, M.B.; Moore, C.B.; Morris, J.; Denning, D.W.; Richardson, M.D. Volume Dependency for Culture of Fungi from Respiratory Secretions and Increased Sensitivity of Aspergillus Quantitative PCR. Mycoses 2014, 57, 69–78.
  88. Richardson, M.; Page, I. Role of Serological Tests in the Diagnosis of Mold Infections. Curr. Fungal Infect. Rep. 2018, 12, 127–136.
  89. Pasqualotto, A.C. Aspergillosis: From Diagnosis to Prevention; Springer: Dordrecht, The Netherlands, 2010; ISBN 9789048124084.
  90. Chapman, N.; Abela-Oversteegen, L.; Doubell, A.; Chowdhary, V.; Gurjav, U.; Ong, M. Neglected Disease Research and Development: A Pivotal Moment for Global Health. 2017. Available online: http://www.finddx.org/wp-content/uploads/2017/02/GF_report16_all_web.pdf (accessed on 20 February 2022).
  91. Molloy, S.F.; Chiller, T.; Greene, G.S.; Burry, J.; Govender, N.P.; Kanyama, C.; Mfinanga, S.; Lesikari, S.; Mapoure, Y.N.; Kouanfack, C.; et al. Cryptococcal Meningitis: A Neglected NTD? PLoS Negl. Trop. Dis. 2017, 11, e0005575.
  92. Kwon-Chung, K.J.; Bennett, J.E.; Wickes, B.L.; Meyer, W.; Cuomo, C.A.; Wollenburg, K.R.; Bicanic, T.A.; Castañeda, E.; Chang, Y.C.; Chen, J.; et al. The Case for Adopting the “Species Complex” Nomenclature for the Etiologic Agents of Cryptococcosis. mSphere 2017, 2, e00357-16.
  93. Maziarz, E.K.; Perfect, J.R. Cryptococcosis. Infect. Dis. Clin. N. Am. 2016, 30, 179–206.
  94. Cogliati, M.; Desnos-Ollivier, M.; McCormick-Smith, I.; Rickerts, V.; Ferreira-Paim, K.; Meyer, W.; Boekhout, T.; Hagen, F.; Theelen, B.; Inácio, J.; et al. Genotypes and Population Genetics of Cryptococcus neoformans and Cryptococcus gattii Species Complexes in Europe and the Mediterranean Area. Fungal Genet. Biol. 2019, 129, 16–29.
  95. Zhou, Y.; Lin, P.C.; Ye, J.R.; Su, S.S.; Dong, L.; Wu, Q.; Xu, H.Y.; Xie, Y.P.; Li, Y.P. The Performance of Serum Cryptococcal Capsular Polysaccharide Antigen Test, Histopathology and Culture of the Lung Tissue for Diagnosis of Pulmonary Cryptococcosis in Patients without HIV Infection. Infect. Drug Resist. 2018, 11, 2483–2490.
  96. Gazzoni, A.F.; Severo, C.B.; Barra, M.B.; Severo, L.C. Atypical Micromorphology and Uncommon Location of Cryptococcosis: A Histopathologic Study Using Special Histochemical Techniques (One Case Report). Mycopathologia 2009, 167, 197–202.
  97. Gazzoni, A.F.; Pegas, K.L.; Severo, L.C. Histopathological Techniques for Diagnosing Cryptococcosis Due to Capsule-Deficient Cryptococcus: Case Report. Rev. Soc. Bras. Med. Trop. 2008, 41, 76–78.
  98. Firacative, C.; Trilles, L.; Meyer, W. MALDI-TOF MS Enables the Rapid Identification of the Major Molecular Types within the Cryptococcus neoformans/C. gattii Species Complex. PLoS ONE 2012, 7, e37566.
  99. McTaggart, L.R.; Lei, E.; Richardson, S.E.; Hoang, L.; Fothergill, A.; Zhang, S.X. Rapid Identification of Cryptococcus neoformans and Cryptococcus gattii by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J. Clin. Microbiol. 2011, 49, 3050–3053.
  100. French, N.; Gray, K.; Watera, C.; Nakiyingi, J.; Lugada, E.; Moore, M.; Lalloo, D.; Whitworth, J.A.G.; Gilks, C.F. Cryptococcal Infection in a Cohort of HIV-1-Infected Ugandan Adults. Aids 2002, 16, 1031–1038.
  101. Kwizera, R.; Omali, D.; Tadeo, K.; Kasibante, J.; Rutakingirwa, M.K.; Kagimu, E.; Ssebambulidde, K.; Williams, D.A.; Rhein, J.; Boulware, D.; et al. Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis. J. Clin. Microbiol. 2021, 59, e02421-20.
  102. Likasitwattanakul, S.; Poneprasert, B.; Sirisanthana, V. Cryptococcosis in HIV-Infected Children. Southeast Asian J. Trop. Med. Public Health 2004, 35, 935–939.
  103. Vidal, J.E.; Boulware, D.R. Lateral Flow Assay for Cryptococcal Antigen: An Important Advance to Improve the Continuum of HIV Care and Reduce Cryptococcal Meningitis-Related Mortality. Rev. Inst. Med. Trop. Sao Paulo 2015, 57, 38–45.
  104. Rolfes, M.; Butler, E.; von Hohenberg, M.; Nabeta, H.; Kwizera, R.; Rajasingham, R.; Bahr, N.; Meya, D.; Boulware, D. Evaluation of a Novel Point-of-Care Lateral Flow Assay to Detect Cryptococcal Antigen in Plasma and CSF. Poster #953, Session 159. In Proceedings of the CROI, Seattle, WA, USA, 8 March 2012; p. 7.
  105. Vijayan, T.; Bauman, S.; Chiller, T.; Klausner, J. Test Performance of a Novel Lateral-Flow Assay to Detect Cryptococcal Disease. 2012. Available online: https://idsa.confex.com/idsa/2012/webprogram/Paper37789.html (accessed on 20 February 2022).
  106. Huang, H.R.; Fan, L.C.; Rajbanshi, B.; Xu, J.F. Evaluation of a New Cryptococcal Antigen Lateral Flow Immunoassay in Serum, Cerebrospinal Fluid and Urine for the Diagnosis of Cryptococcosis: A Meta-Analysis and Systematic Review. PLoS ONE 2015, 10, e0127117.
  107. Vidal, J.E.; Toniolo, C.; Paulino, A.; Colombo, A.L.; Martins, M.D.A.; da Silva Meira, C.; Azevedo, R.G.S.; Pereira-Chioccola, V.L.; Gomes, H.R.; Dos Santos Lazera, M.; et al. Performance of Cryptococcal Antigen Lateral Flow Assay in Serum, Cerebrospinal Fluid, Whole Blood, and Urine in HIV-Infected Patients with Culture-Proven Cryptococcal Meningitis Admitted at a Brazilian Referral Center. Rev. Inst. Med. Trop. Sao Paulo 2018, 60.
  108. Magambo, K.A.; Kalluvya, S.E.; Kapoor, S.W.; Seni, J.; Chofle, A.A.; Fitzgerald, D.W.; Downs, J.A. Utility of Urine and Serum Lateral Flow Assays to Determine the Prevalence and Predictors of Cryptococcal Antigenemia in HIV-Positive Outpatients Beginning Antiretroviral Therapy in Mwanza, Tanzania. J. Int. AIDS Soc. 2014, 17, 19040.
  109. Longley, N.; Jarvis, J.N.; Meintjes, G.; Boulle, A.; Cross, A.; Kelly, N.; Govender, N.P.; Bekker, L.G.; Wood, R.; Harrison, T.S. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. Clin. Infect. Dis. 2016, 62, 581–587.
  110. Mfinanga, S.; Chanda, D.; Kivuyo, S.L.; Guinness, L.; Bottomley, C.; Simms, V.; Chijoka, C.; Masasi, A.; Kimaro, G.; Ngowi, B.; et al. Cryptococcal Meningitis Screening and Community-Based Early Adherence Support in People with Advanced HIV Infection Starting Antiretroviral Therapy in Tanzania and Zambia: An Open-Label, Randomised Controlled Trial. Lancet 2015, 385, 2173–2182.
  111. Letang, E.; Müller, M.C.; Ntamatungiro, A.J.; Kimera, N.; Faini, D.; Furrer, H.; Battegay, M.; Tanner, M.; Hatz, C.; Boulware, D.R.; et al. Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. Open Forum Infect. Dis. 2015, 2, ofv046.
  112. Pac, L.; Horwitz, M.M.; Namutebi, A.M.; Auerbach, B.J.; Semeere, A.; Namulema, T.; Schwarz, M.; Bbosa, R.; Muruta, A.; Meya, D.B.; et al. Implementation and Operational Research: Integrated Pre-Antiretroviral Therapy Screening and Treatment for Tuberculosis and Cryptococcal Antigenemia. J. Acquir. Immune Defic. Syndr. 2015, 68, e69–e76.
  113. Kaplan, J.E.; Vallabhaneni, S.; Smith, R.M.; Chideya-Chihota, S.; Chehab, J.; Park, B. Cryptococcal Antigen Screening and Early Antifungal Treatment to Prevent Cryptococcal Meningitis: A Review of the Literature. J. Acquir. Immune Defic. Syndr. 2015, 68, S331–S339.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biotechnology & Applied Microbiology; Biochemistry & Molecular Biology; Others
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Moisés Morais Inácio
,
Vanessa Rafaela Milhomem Cruz-Leite
,
André Luís Elias Moreira
,
Karine Mattos
,
Juliano Domiraci Paccez
,
Orville Hernandez Ruiz
,
James Venturini
,
Marcia de Souza Carvalho Melhem
,
Anamaria Mello Miranda Paniago
,
Célia Maria de Almeida Soares
,
Simone Schneider Weber
,
Clayton Luiz Borges
View Times: 467
Revisions: 2 times (View History)
Update Date: 29 Jun 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback